Transcranial Direct Current Brain Stimulation to Treat Patients With Childhood-Onset Schizophrenia
| Status: | Terminated |
|---|---|
| Conditions: | Schizophrenia, Psychiatric |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 10 - Any |
| Updated: | 4/5/2019 |
| Start Date: | September 17, 2008 |
| End Date: | August 18, 2015 |
Safety of Transcranial Direct Current Brain Stimulation (TDCS) for Improvement of Psychotic Symptoms and Cognitive Functioning in Childhood Onset Schizophrenia (COS)
This study will test whether transcranial direct current stimulation (TDCS) can be used
safely in children with schizophrenia and if it can improve memory and attention span or
auditory hallucinations in these children, at least temporarily. TDCS has temporarily
improved memory and attention span in healthy adults and a similar method called TMS has
relieved auditory hallucinations in adults with schizophrenia. For the TDCS procedure, the
child sits in a chair and two soft sponge electrodes are placed on the child s forehead and
held in place with a soft wrapping. One sponge electrode is placed on an arm. The electrodes
are attached to a stimulator with a wire.
Children with schizophrenia who meet the following criteria may be eligible for this study:
- Are 10 yrs or older age.
- Are participating in NIH protocol 03-M-0035.
- Are on a stable medication regimen for at least 6 months.
- Have problems with memory and attention span or have auditory hallucinations.
Participants are randomly assigned to receive either real or sham TDCS on an inpatient or
outpatient basis in 20-minute sessions daily, except weekends, for 10 days. For real TDCS,
patients receive stimulation to the front of the brain. For sham stimulation, the children
have electrodes placed on the forehead, but no actual stimulation is delivered. In addition
to TDCS, patients have the following procedures:
- Checks of blood pressure, pulse and breathing rate before, during and right after each
stimulation and again 8 hours later.
- Electrocardiogram (EKG) and electroencephalogram (EEG) before starting stimulation and
after completing the 10 days of TDCS.
- Interviews and examinations to check for side effects of TDCS.
- Pen-and-paper or computer tests of learning, attention and memory.
- At the end of the 10 sessions, children who were in the sham TDCS group are offered the
same number of sessions of active TDCS.
- Follow-up telephone call 1 month after the end of stimulation to see how the child is
doing.
- 1- to 2-day outpatient visit 6 months after the stimulation. This visit includes
interviews with the parent and the child, rating of the child s psychiatric symptoms,
and pen-and-paper or computer tests of thinking, attention and memory.
safely in children with schizophrenia and if it can improve memory and attention span or
auditory hallucinations in these children, at least temporarily. TDCS has temporarily
improved memory and attention span in healthy adults and a similar method called TMS has
relieved auditory hallucinations in adults with schizophrenia. For the TDCS procedure, the
child sits in a chair and two soft sponge electrodes are placed on the child s forehead and
held in place with a soft wrapping. One sponge electrode is placed on an arm. The electrodes
are attached to a stimulator with a wire.
Children with schizophrenia who meet the following criteria may be eligible for this study:
- Are 10 yrs or older age.
- Are participating in NIH protocol 03-M-0035.
- Are on a stable medication regimen for at least 6 months.
- Have problems with memory and attention span or have auditory hallucinations.
Participants are randomly assigned to receive either real or sham TDCS on an inpatient or
outpatient basis in 20-minute sessions daily, except weekends, for 10 days. For real TDCS,
patients receive stimulation to the front of the brain. For sham stimulation, the children
have electrodes placed on the forehead, but no actual stimulation is delivered. In addition
to TDCS, patients have the following procedures:
- Checks of blood pressure, pulse and breathing rate before, during and right after each
stimulation and again 8 hours later.
- Electrocardiogram (EKG) and electroencephalogram (EEG) before starting stimulation and
after completing the 10 days of TDCS.
- Interviews and examinations to check for side effects of TDCS.
- Pen-and-paper or computer tests of learning, attention and memory.
- At the end of the 10 sessions, children who were in the sham TDCS group are offered the
same number of sessions of active TDCS.
- Follow-up telephone call 1 month after the end of stimulation to see how the child is
doing.
- 1- to 2-day outpatient visit 6 months after the stimulation. This visit includes
interviews with the parent and the child, rating of the child s psychiatric symptoms,
and pen-and-paper or computer tests of thinking, attention and memory.
Background: The majority (about 75%) of patients with childhood onset schizophrenia still
have impairing cognitive and psychotic symptoms after drug treatment optimization. Recent
studies with transcranial magnetic stimulation (TMS) indicate moderate efficacy in symptom
reduction in adult patients with schizophrenia. Transcranial direct current stimulation
(TDCS) may be a safe and effective additional treatment of residual symptoms of schizophrenia
in medication stable patients. Recent research into adult-onset schizophrenia established
both safety and efficacy in 20-minute daily DC polarization (TDSC).
Objective: To establish whether bilateral DC polarization (using TDCS) of either dorsolateral
prefrontal cortex or superior temporal cortex is safe in patients with childhood onset
schizophrenia and whether it is associated with improvement in cognitive performance or
reduction in auditory hallucination (psychotic symptoms) respectively.
Study population: Up to 40 patients with schizophrenia, ages 10 and older will be recruited.
All patients will be on optimized medications for at least 2 months prior to this study.
Design: The design has two concurrent study options; both double-blind sham controlled, with
10-day, 40-minute daily DC polarization. Patients will be selected for one of the two
treatment options: 1. Bilateral Anodal DC polarization of prefrontal cortex or 2. Bilateral
Cathodal DC polarization of superior temporal cortex. A small battery powered device
(Phoresor II Auto Model PM850) approved by the FDA for iontophoretic transdermal drug
delivery will be used to administer the DC current. Sham treatment will be electrode
placement without current.
Outcome Measures: The primary outcome measure would be to determine whether TDCS treatment is
safe in children and adults with schizophrenia, as assessed by vital signs monitoring,
reporting/evaluation of adverse effects, clinical ratings and neurocognitive performance.
Secondary outcome measures: The secondary outcome measures would be improvement on 1)
Hallucination Change Scale (HCS) and Auditory Hallucinations Rating Scale (AHRS) for auditory
hallucinations; SAPS, SANS and BPRS scales for psychotic symptoms and 2) performance on the
working memory (verbal and non verbal), attention/vigilance, and verbal learning sub tests
for cognitive improvement.
Exploratory Measure: Effect of DC polarization on regional GM cortical thickness in DLPFC and
STG regions.
have impairing cognitive and psychotic symptoms after drug treatment optimization. Recent
studies with transcranial magnetic stimulation (TMS) indicate moderate efficacy in symptom
reduction in adult patients with schizophrenia. Transcranial direct current stimulation
(TDCS) may be a safe and effective additional treatment of residual symptoms of schizophrenia
in medication stable patients. Recent research into adult-onset schizophrenia established
both safety and efficacy in 20-minute daily DC polarization (TDSC).
Objective: To establish whether bilateral DC polarization (using TDCS) of either dorsolateral
prefrontal cortex or superior temporal cortex is safe in patients with childhood onset
schizophrenia and whether it is associated with improvement in cognitive performance or
reduction in auditory hallucination (psychotic symptoms) respectively.
Study population: Up to 40 patients with schizophrenia, ages 10 and older will be recruited.
All patients will be on optimized medications for at least 2 months prior to this study.
Design: The design has two concurrent study options; both double-blind sham controlled, with
10-day, 40-minute daily DC polarization. Patients will be selected for one of the two
treatment options: 1. Bilateral Anodal DC polarization of prefrontal cortex or 2. Bilateral
Cathodal DC polarization of superior temporal cortex. A small battery powered device
(Phoresor II Auto Model PM850) approved by the FDA for iontophoretic transdermal drug
delivery will be used to administer the DC current. Sham treatment will be electrode
placement without current.
Outcome Measures: The primary outcome measure would be to determine whether TDCS treatment is
safe in children and adults with schizophrenia, as assessed by vital signs monitoring,
reporting/evaluation of adverse effects, clinical ratings and neurocognitive performance.
Secondary outcome measures: The secondary outcome measures would be improvement on 1)
Hallucination Change Scale (HCS) and Auditory Hallucinations Rating Scale (AHRS) for auditory
hallucinations; SAPS, SANS and BPRS scales for psychotic symptoms and 2) performance on the
working memory (verbal and non verbal), attention/vigilance, and verbal learning sub tests
for cognitive improvement.
Exploratory Measure: Effect of DC polarization on regional GM cortical thickness in DLPFC and
STG regions.
- INCLUSION CRITERIA:
COS patients (age 10 and above) recruited and followed under the current protocol
03-M-0035, where subjects have been stable (in the judgment of the investigator) on their
medications for 2 months with or without PRN medications but continue to experience either:
1. Cognitive difficulties as evidenced by information from parents and teachers, clinical
interview, and performance (below average based on published norms for each test) on
neurocognitive tests (WMS-III Spatial Span (nonverbal) and WMS-III Letter-Number
Sequencing (verbal) attention/vigilance (CPT-IP), and verbal learning (HVLT-R), all
sub tests of the NIMH MATRICS battery).
2. Significant auditory hallucinations as measured by SAPS (scores above 2) or BPRS
(scores above 3).
EXCLUSION CRITERIA:
In addition to the exclusion criteria under protocol 03-M-0035, the following will be
exclusionary:
1. Broken or abnormal skin in the area of the electrodes.
2. Presence of metal in the cranial cavity.
3. Holes in the skull from trauma or surgery.
4. Positive pregnancy test.
5. Presence of other psychiatric illness (e.g. severe anxiety, OCD etc) unless the
patient has been on stable medication for the prior 2 months
We found this trial at
1
site
9000 Rockville Pike
Bethesda, Maryland 20892
Bethesda, Maryland 20892
Click here to add this to my saved trials
